Curated News
By: NewsRamp Editorial Staff
September 23, 2026
Kairos Pharma to Present Cancer Drug Resistance Strategy at Boston Conference
TLDR
- Kairos Pharma presents KROS-101 at the Discovery on Target conference, showcasing a strategy to overcome cancer drug resistance and gain a competitive edge.
- Kairos Pharma's KROS-101 targets GITR to boost T-cell function and anti-tumor activity, as explained by CSO Neil Bhowmick at the Boston conference.
- Kairos Pharma's work on KROS-101 and ENV-105 aims to reverse drug resistance, offering hope for more effective cancer treatments and better patient outcomes.
- At the 24th Annual Discovery on Target conference, Kairos Pharma will discuss targeting GITR to fight cancer, highlighting innovative approaches to immunotherapy.
Impact - Why it Matters
Kairos Pharma’s participation in the Discovery on Target conference highlights its innovative approach to overcoming cancer drug resistance, a major challenge in oncology that limits the long-term effectiveness of many treatments. By targeting mechanisms like CD105 and GITR, Kairos aims to restore the efficacy of standard therapies and enhance anti-tumor immune responses. If successful, these strategies could significantly improve outcomes for patients with solid tumors and other cancers, addressing a critical unmet need. For investors, the presentation may provide visibility into the company’s pipeline and potential, especially as it advances its lead candidate ENV-105. The event also underscores the role of platforms like NetworkNewsWire and IBN in disseminating important developments to the investment community.
Summary
Kairos Pharma (NYSE American: KAPA) announced that President and Chief Scientific Officer Neil Bhowmick will present and moderate at the 24th Annual Discovery on Target Drug Discovery Conference, held Sept. 28-Oct. 1 in Boston. Bhowmick will moderate a Sept. 30 breakout session titled “Winning the Race against Cancer Therapy Resistance,” focusing on Kairos’ strategy to target cancer drug resistance and extend the efficacy of previously effective drug candidates. He will also deliver an oral plenary presentation on Sept. 30 at 2:35 p.m. Eastern on KROS-101, the company’s drug candidate targeting solid tumors. The presentation will highlight KROS-101’s targeting of GITR (“Glucocorticoid-Induced TNF Receptor”) to increase T-cell function and expand effector T-cells with anti-tumor activity.
Based in Los Angeles, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For full details, visit https://nnw.fm/DoHxL.
The announcement was distributed through NetworkNewsWire (“NNW”), a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma to Present Cancer Drug Resistance Strategy at Boston Conference
